SSSandeep Seth

Sandeep Seth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandeep Seth has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    VERINA: A Phase IV Prospective Multicenter Study of Vericiguat in Indian Patients with Worsening Heart Failure and Reduced Ejection Fraction

    by Sandeep Seth, Atul Abhyankar, Jabir Abdullakutty, Suvro Banerjee, Kamal Sharma, Vinod Vijan, Nirav Chandulal Bhalani, Vijay Kumar Chopra, Rakesh Kumar Aggarwal, Abraham Oomman, et al.

    Introduction Patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain at high risk of cardiovascular (CV) death and hospitalization following a worsening heart-failure event. Data on vericiguat, a prescription oral medication used to treat symptomatic chronic HF, in adult Indian patients are limited. Methods Adults with chronic HFrEF and a worsening heart-failure event were enrolled in a prospective, multicenter, open-label, single-arm phase IV study design. Participants received vericiguat in addition to foundational medical therapy (FMT) and were followed for approximately 48 weeks. The primary endpoint was CV death or first hospitalization for HF. Secondary endpoints included CV death, first hospitalization for HF, all-cause death or first hospitalization for HF, all-cause death and safety outcomes. Results Of 231 patients who underwent screening, 205 received vericiguat and comprised the safety analysis set; of these, 203 patients constituted the full analysis set. The mean age of participants was 58 years. Baseline use of angiotensin receptor–neprilysin inhibitors and sodium–glucose cotransporter-2 inhibitors was 52.7% and 75.6%, respectively. At week 48, Kaplan–Meier (KM) estimates were 10.1% for the primary endpoint, 3.3% for CV death, 9.1% for first hospitalization for HF, 11.5% for all-cause death or first hospitalization for HF, and 5.9% for all-cause death. Attainment of the target dose was 91.6%, with 69.5% of participants reaching and maintaining 10 mg by week 4. Study drug-related adverse events (AEs) were reported in 3.4% of participants, and treatment-emergent AEs requiring discontinuation in 2.0% of participants. Conclusion In Indian patients with worsening HFrEF, high target-dose attainment and no new safety signals were observed during 48 weeks of vericiguat treatment. Trial Registration Clinical Trials Registry–India: CTRI/2022/11/047636.

  • Open Access

    Indian Expert Consensus on Heart Failure with Preserved Ejection Fraction: A Phenotype-based Approach to Diagnosis and Management

    by Sandeep Seth, Vijay Kumar Chopra, Nakul Sinha, Tiny Nair, Michael Bohm, Jps Sawhney, Abraham Oomman, Aparna Jaswal, Arun Gopi, Sarita Rao, et al.

    Background: The burden of heart failure (HF) with preserved ejection fraction (EF) is increasing in India. Compared with Western populations, Indian patients often present at a younger age with a high burden of diabetes, chronic kidney disease, central adiposity, anemia, chronic obstructive airway disease, peripheral artery disease, and ischemic heart disease. These differences pose challenges for the implementation of existing EF-based management strategies and support the need for India-specific guidance. Objectives: The objectives of this study were to develop India-specific consensus recommendations for the diagnosis, phenotypic assessment, and management of HF with preserved EF (HFpEF) across diverse healthcare settings. Methodology: A modified Delphi consensus process involving 25 HF experts from India and Europe was used to formulate recommendations based on a review of contemporary evidence and structured expert voting. Results: Consensus was achieved on recommendations covering disease recognition, diagnosis, phenotype-based assessment, pharmacotherapy, and models of care, with emphasis on their applicability to Indian clinical practice. The consensus recognizes emerging evidence supporting sodium–glucose cotransporter-2 inhibitors as foundational therapy, mineralocorticoid receptor antagonists, particularly finerenone, in appropriate patients, and glucagon-like peptide-1 receptor agonists in selected phenotypes of HFpEF, especially those with obesity and metabolic dysfunction. While the consensus is framed around HFpEF, it also acknowledges that much of the evidence supporting these therapies includes patients with left ventricular EF between 40% and 50%, in whom similar therapeutic benefits have been demonstrated. Conclusion: This consensus provides practical and phenotype-based recommendations for the diagnosis and management of HFpEF in India. These recommendations are intended to support earlier diagnosis, facilitate implementation of evidence-based therapies, reduce therapeutic inertia, and identify priorities for future research and prospective validation.

  • Unraveling the interplay between RAS axes and NOX signaling in fibroblasts during cardiac fibrosis

    by Gauri Chaturvedi, Anita Chauhan, Nandini Dubey, Sandeep Seth, Jagriti Bhatia, Subhash Chandra Yadav, Harlokesh Narayan Yadav

    Cardiac fibrosis results from cardiovascular diseases (CVDs) and is characterized by excessive extracellular matrix (ECM) accumulation, particularly collagen, leading to cardiac dysfunction. Despite the availability of treatments for CVDs, no targeted therapies are available to prevent disease progression to irreversible stages. Further research is needed to explore the pathways and signaling molecules involved in this progression. The renin-angiotensin system (RAS) plays a significant role, with pharmacological agents targeting its harmful axis, i.e., Angiotensin-converting enzyme (ACE)/Angiotensin II (Ang II)/Angiotensin 1 receptor (AT1R) axis, while an antagonistic axis, ACE2/Angiotensin 1–7 (Ang 1–7)/mitochondrial assembly receptor (MasR) axis offers cardioprotective effects. Reactive oxygen species (ROS) also contribute to CVDs, with NADPH oxidases (NOXes) being key inducers of ROS. NOX1, NOX2, NOX4, and NOX5 are upregulated in pathological conditions, exacerbating the disease. This review focuses on the mechanisms by which the ACE/Ang II/AT1R and ACE2/Ang 1–7/MasR axes regulate NOX activity, aiming to enhance our understanding of future targeted therapies.


  • Open Access

    rECGnition_v2.0: Self-Attentive Canonical Fusion of ECG and Patient Data using deep learning for effective Cardiac Diagnostics

    by Shreya Srivastava, Durgesh Kumar, Ram Jiwari, Sandeep Seth, Deepak Sharma

    The variability in ECG readings influenced by individual patient characteristics has posed a considerable challenge to adopting automated ECG analysis in clinical settings. A novel feature fusion technique termed SACC (Self Attentive Canonical Correlation) was proposed to address this. This technique is combined with DPN (Dual Pathway Network) and depth-wise separable convolution to create a robust, interpretable, and fast end-to-end arrhythmia classification model named rECGnition_v2.0 (robust ECG abnormality detection). This study uses MIT-BIH, INCARTDB and EDB dataset to evaluate the efficiency of rECGnition_v2.0 for various classes of arrhythmias. To investigate the influence of constituting model components, various ablation studies were performed, i.e. simple concatenation, CCA and proposed SACC were compared, while the importance of global and local ECG features were tested using DPN rECGnition_v2.0 model and vice versa. It was also benchmarked with state-of-the-art CNN models for overall accuracy vs model parameters, FLOPs, memory requirements, and prediction time. Furthermore, the inner working of the model was interpreted by comparing the activation locations in ECG before and after the SACC layer. rECGnition_v2.0 showed a remarkable accuracy of 98.07% and an F1-score of 98.05% for classifying ten distinct classes of arrhythmia with just 82.7M FLOPs per sample, thereby going beyond the performance metrics of current state-of-the-art (SOTA) models by utilizing MIT-BIH Arrhythmia dataset. Similarly, on INCARTDB and EDB datasets, excellent F1-scores of 98.01% and 96.21% respectively was achieved for AAMI classification. The compact architectural footprint of the rECGnition_v2.0, characterized by its lesser trainable parameters and diminished computational demands, unfurled several advantages including interpretability and scalability.

  • Open Access

    Strategies to Optimize Management of Outpatient Worsening Heart Failure: A National Consensus from India

    by Sandeep Seth, Vijay Kumar Chopra, Raja Ram Mantri, Sunil K. Modi, Sanjay Mittal, Jayagopal Pathiyil Balagopalan, Vinayak Aggarwal, Rajiv Mehrotra, Sundeep Mishra, B. S. Vivek, et al.

    Background: Worsening heart failure (WHF) is characterized by the progression of symptoms in patients with established HF, necessitating intensified treatment, typically with diuretics. Outpatient (OP) management of WHF offers an alternative to hospitalization, as many patients experience a gradual onset of symptoms, allowing timely intervention. However, OP WHF is often underrecognized and excluded from clinical trials, highlighting the need for structured guidance. This expert consensus aims to address this gap by providing clinical practice recommendations for OP WHF management. Methodology: A panel of Indian cardiologists convened for an expert meeting moderated by a leading cardiologist. Based on clinical evidence, expert insights, and live polling, consensus recommendations were developed. Results: Experts agreed that WHF is defined by symptom worsening despite standard HF therapy, decompensation in chronic HF, and an increase in oral or intravenous diuretic dose. Vericiguat was recognized as suitable for patients with reduced eGFR (<30 mL/min/1.73 m²), unlike angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEi/ARB/ARNi) and digoxin. While ACEi/ARB/ARNi doses may be reduced in WHF with worsening renal function, beta-blockers should be maintained as long as possible. OP management should prioritize early vericiguat initiation alongside rapid HF therapy optimization. About 44% of experts recommended initiating vericiguat at the first follow-up (3–7 days postdischarge), whereas 33.3% preferred it as a last-line option. Management of end-stage heart failure with advanced options like assist devices and transplants is needed with failure of drug therapy, persisting end-organ failure, and repeated hospitalization. Conclusion: This consensus highlights early OP department (OPD)-based recognition of WHF, OPD-based structured HF therapy optimization, and early vericiguat initiation to improve WHF management in outpatient settings.


  • Lung water estimation on cardiac magnetic resonance imaging for predicting adverse cardiovascular outcomes in patients with heart failure

    by Mansi Verma, Priya Jagia, Ambuj Roy, Pradeep Kumar Chaturvedi, Sanjeev Kumar, Sandeep Seth, Vishwajeet Singh, Vineeta Ojha, Niraj Nirmal Pandey

    Objectives: Pulmonary congestion is a central feature of heart failure (HF) seen in acute decompensated state as well as in chronic stable disease. The present study sought to determine whether simplified cardiac magnetic resonance imaging (CMR)-derived lung water density (LWD) measurement has prognostic relevance in predicting adverse cardiovascular outcomes in patients with HF and left ventricular ejection fraction (LVEF) 18.1%) had higher incidence of adverse cardiovascular outcomes compared to patients with “dry lungs”. LWD was an independent predictor of adverse cardiovascular outcomes in multivariable analysis. At the optimal cut-off of LWD > 23.38%, the sensitivity and specificity were 91.67 and 91.18%, respectively, to predict adverse cardiovascular outcomes. Conclusion: LWD on CMR is independently associated with increased risk of mortality and HF-related hospitalization in HF patients with LVEF<50%. Advances in knowledge: Non-invasive quantitative estimation of LWD on CMR can improve risk stratification and guide management in HF patients.


  • Expert Opinion on the Identification and Pharmacological Management of Worsening Heart Failure

    by Sandeep Seth, Johann Bauersachs, Sanjay Mittal, Vishal Rastogi, Rajeev Kumar Rajput, Dheeraj Gandotra, Ripen Gupta, Manoj Sahu, S N Pathak, Mohit Bhagwati, et al.

    Worsening heart failure (WHF) is a distinct under-diagnosed and under-treated condition, independent of location of care. Heart failure (HF) progression is punctuated by repeated WHF events, each resulting in reduced cardiac function. One-third of the patients with HF with reduced ejection fraction experience a decompensation event. These decompensation events often result in the emergency department visits and HF hospitalization. Despite its inclusion in recent guidelines, there is no precise definition of WHF or its various forms. It is worth noting that WHF signals a need for treatment optimization as per guideline-directed medical therapy and the addition of novel drugs like a stimulator of soluble guanylate cyclase that benefit this high-risk patient population. This practical document is based on the expert opinion of cardiologists, cardiothoracic surgeons, and physicians that discussed the definition, assessment, pharmacological management, and monitoring of WHF patients in a hospitalized setting. In addition, there is also a need for an expert opinion for the management of WHF in an outpatient setting.


  • Imaging of cardiac sympathetic dysfunction with 18F-FDOPA PET/CT in patients with heart failure: a pilot study

    by Thayumanavan Thanigainathan, Anshul Sharma, Chetan Patel, Sandeep Seth, Ambuj Roy, Anil Kumar Pandey, Priyanka Gupta, Rajeev Kumar, Praveen Kumar, Chandra Shekhar Bal


  • Prognostic Value of Resting Heart Rate and Heart Rate Recovery in Acute Decompensated Heart Failure

    by Mohammad Azharuddin Malik, Raghav Bansal, Sandeep Seth, Neeraj Parakh, Ambuj Roy, Vinay Kumar Bahl

    Background: Acute decompensated heart failure (ADHF) remains a problem of public health concern. Better prognostication is needed to predict outcomes in these patients. Resting heart rate (HR) and HR recovery (HRR) have been proposed as prognostic markers for future events. Materials and Methods: Twenty-five patients admitted for ADHF were enrolled. Baseline demographic data and routine investigations were noted for all. After medical stabilization, before discharge, a 6-min walk test (6-MWT) was performed for all patients. Resting HR at the start, maximum HR achieved, chronotropic reserve, and hearing rate recovery was observed 1 min after completing the exercise. All patients were followed for the appearance of a primary composite outcome consisting of death, heart transplant, or hospitalization for HF. Results: Primary composite outcome occurred in 6 (24%) patients, including 3 (12%) deaths and 3 (12%) HF hospitalizations. The patients who had the primary outcome had a trend toward a shorter distance of walking of 6 min (154.33 ± 51.84 vs. 210.53 ± 78.62, P = 0.16). Resting HR was significantly higher among patients with primary outcome (113.00 ± 17.74 vs. 89.58 ± 16.25, P ≤ 0.01). HRR and chronotropic reserve were significantly lower in patients with primary outcome (7.33 ± 1.75 vs. 17.42 ± 9.47, P < 0.01 and 15.00 ± 11.93 vs. 34.94 ± 19.81, P = 0.02; respectively). A resting HR of 109/min, HRR of 9/min, and chronotropic reserve of 20/min had sensitivity/specificity for predicting the primary outcome of 83.33%/89.47%, 84.21%/83.33%, and 84.21% a/as 83.33%, respectively. Conclusions: Elevated resting HR, decreased HR reserve, and decreased chronotropic reserve are associated with hospital readmissions and decreased event-free survival in patients with ADHF. Resting HR is especially helpful in this regard given the simplicity and ease of its assessment.